{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:09:42Z","timestamp":1793106582471,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-006-024"],"award-info":[{"award-number":["110-2314-B-006-024"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012537","name":"Ditmanson Medical Foundation Chia-Yi Christian Hospital","doi-asserted-by":"publisher","award":["NCKUCYC-P-11101-2"],"award-info":[{"award-number":["NCKUCYC-P-11101-2"]}],"id":[{"id":"10.13039\/501100012537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cisplatin-based chemotherapy is the first line of treatment for bladder cancer. However, cisplatin induces muscle wasting associated with NF-\u03baB and cancer cachexia. HOTAIR, an oncogenic long non-coding RNA (lncRNA), promotes cancer progression in different cancers. Crosstalk between HOTAIR and NF-\u03baB is documented. Prothymosin \u03b1 (ProT) plays important roles in cancer progression and inflammation. However, the potential link between HOTAIR, ProT, and cisplatin-induced cancer cachexia remains unexplored. Here, we investigated the contribution of HOTAIR in cisplatin-induced cancer cachexia and dissected the potential signaling cascade involving the epidermal growth factor receptor (EGFR), ProT, NF-\u03baB, and HOTAIR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Expression of ProT and HOTAIR transcripts and their correlations in tumor tissues of bladder cancer patients and bladder cancer cell lines were determined by RT-qPCR. Next, levels of phospho-EGFR, EGFR, phospho-NF-\u03baB, and NF-\u03baB were examined by immunoblot analysis in human bladder cancer cells treated with cisplatin. Expression of HOTAIR in cisplatin-treated cells was also assessed by RT-qPCR. Pharmacological inhibitors and overexpression and knockdown approaches were exploited to decipher the signaling pathway. The murine C2C12 myoblasts were used as an in vitro muscle atrophy model. The syngeneic murine MBT-2 bladder tumor was used to investigate the role of mouse Hotair in cisplatin-induced cancer cachexia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Expression of ProT and HOTAIR was higher in bladder tumors than in normal adjacent tissues. There were positive correlations between ProT and HOTAIR expression in clinical bladder tumors and bladder cancer cell lines. Cisplatin treatment increased EGFR and NF-\u03baB activation and upregulated ProT and HOTAIR expression in bladder cancer cells. ProT overexpression increased, whereas ProT knockdown decreased, HOTAIR expression. Notably, cisplatin-induced HOTAIR upregulation was abrogated by EGFR inhibitors or ProT knockdown. ProT-induced HOTAIR overexpression was diminished by NF-\u03baB inhibitors. HOTAIR overexpression enhanced, whereas its knockdown reduced, cell proliferation, cachexia-associated pro-inflammatory cytokine expression, and muscle atrophy. Cachexia-associated symptoms were ameliorated in mice bearing Hotair-knockdown bladder tumors undergoing cisplatin treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrate for the first time a critical role for HOTAIR and identify the involvement of the EGFR-ProT-NF-\u03baB-HOTAIR signaling axis in cisplatin-induced cachexia in bladder cancer and likely other cancers. Our findings also provide therapeutic targets for this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-022-00887-y","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:03:24Z","timestamp":1670292204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer"],"prefix":"10.1186","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-4552","authenticated-orcid":false,"given":"Che-Yuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Che","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Teng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ting","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hui","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Shyan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chih","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Li","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia-Shing","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-9406","authenticated-orcid":false,"given":"Chao-Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"6","key":"887_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cytogfr.2006.09.006","volume":"17","author":"A Saini","year":"2006","unstructured":"Saini A, Al-Shanti N, Stewart CE. Waste management\u2014cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006;17(6):475\u201386.","journal-title":"Cytokine Growth Factor Rev"},{"key":"887_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.597675","volume":"11","author":"JM Webster","year":"2020","unstructured":"Webster JM, Kempen L, Hardy RS, Langen RCJ. Inflammation and skeletal muscle wasting during cachexia. Front Physiol. 2020;11: 597675.","journal-title":"Front Physiol"},{"issue":"3","key":"887_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3945\/ajcn.113.058388","volume":"98","author":"CM Op den Kamp","year":"2013","unstructured":"Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, Laugs F, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98(3):738\u201348.","journal-title":"Am J Clin Nutr"},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnut.2020.00004","volume":"7","author":"D Riccardi","year":"2020","unstructured":"Riccardi D, das Neves RX, de Matos-Neto EM, Camargo RG, Lima J, Radloff K, et al. Plasma lipid profile and systemic inflammation in patients with cancer cachexia. Front Nutr. 2020;7:4.","journal-title":"Front Nutr"},{"issue":"1","key":"887_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-00288-6","volume":"10","author":"V Rausch","year":"2021","unstructured":"Rausch V, Sala V, Penna F, Porporato PE, Ghigo A. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis. 2021;10(1):1.","journal-title":"Oncogenesis"},{"issue":"4","key":"887_CR6","first-page":"618","volume":"2","author":"T Zhang","year":"2021","unstructured":"Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-kappaB signaling in inflammation and cancer. MedComm (2020). 2021;2(4):618\u201353.","journal-title":"MedComm (2020)"},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-981-13-1435-3_12","volume":"1088","author":"A Thoma","year":"2018","unstructured":"Thoma A, Lightfoot AP. NF-kB and inflammatory cytokine signalling: role in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:267\u201379.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"887_CR8","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.3390\/ijms19102999","volume":"19","author":"H Fukushima","year":"2018","unstructured":"Fukushima H, Takemura K, Suzuki H, Koga F. Impact of sarcopenia as a prognostic biomarker of bladder cancer. Int J Mol Sci. 2018;19(10):2999.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"887_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/BLC-180188","volume":"4","author":"KJ Rimar","year":"2018","unstructured":"Rimar KJ, Glaser AP, Kundu S, Schaeffer EM, Meeks J, Psutka SP. Changes in lean muscle mass associated with neoadjuvant platinum-based chemotherapy in patients with muscle invasive bladder cancer. Bladder Cancer. 2018;4(4):411\u20138.","journal-title":"Bladder Cancer"},{"issue":"2","key":"887_CR10","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.4081\/ejtm.2018.7590","volume":"28","author":"JS Damrauer","year":"2018","unstructured":"Damrauer JS, Stadler ME, Acharyya S, Baldwin AS, Couch ME, Guttridge DC. Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia. Eur J Transl Myol. 2018;28(2):7590.","journal-title":"Eur J Transl Myol"},{"issue":"4","key":"887_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/ijms21041242","volume":"21","author":"E Conte","year":"2020","unstructured":"Conte E, Bresciani E, Rizzi L, Cappellari O, De Luca A, Torsello A, et al. Cisplatin-induced skeletal muscle dysfunction: mechanisms and counteracting therapeutic strategies. Int J Mol Sci. 2020;21(4):1242.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"887_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.taap.2014.05.001","volume":"278","author":"H Sakai","year":"2014","unstructured":"Sakai H, Sagara A, Arakawa K, Sugiyama R, Hirosaki A, Takase K, et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicol Appl Pharmacol. 2014;278(2):190\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 4","key":"887_CR13","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","volume":"37","author":"RI Nicholson","year":"2001","unstructured":"Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9-15.","journal-title":"Eur J Cancer"},{"issue":"7","key":"887_CR14","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/1097-0142(19900401)65:7<1619::AID-CNCR2820650728>3.0.CO;2-Q","volume":"65","author":"DE Neal","year":"1990","unstructured":"Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990;65(7):1619\u201325.","journal-title":"Cancer"},{"issue":"57","key":"887_CR15","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1038\/sj.onc.1205980","volume":"21","author":"M Benhar","year":"2002","unstructured":"Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene. 2002;21(57):8723\u201331.","journal-title":"Oncogene"},{"issue":"6565","key":"887_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/379557a0","volume":"379","author":"H Daub","year":"1996","unstructured":"Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379(6565):557\u201360.","journal-title":"Nature"},{"issue":"55","key":"887_CR17","doi-asserted-by":"publisher","first-page":"30594","DOI":"10.18632\/oncotarget.25748","volume":"9","author":"V Hugo de Almeida","year":"2018","unstructured":"Hugo de Almeida V, Guimaraes IDS, Almendra LR, Rondon AMR, Tilli TM, de Melo AC, et al. Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget. 2018;9(55):30594\u2013609.","journal-title":"Oncotarget"},{"issue":"3","key":"887_CR18","first-page":"249","volume":"1","author":"SC Hsu","year":"2009","unstructured":"Hsu SC, Miller SA, Wang Y, Hung MC. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res. 2009;1(3):249\u201358.","journal-title":"Am J Transl Res"},{"issue":"7","key":"887_CR19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2007.05.022","volume":"129","author":"JL Rinn","year":"2007","unstructured":"Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311\u201323.","journal-title":"Cell"},{"issue":"7291","key":"887_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071\u20136.","journal-title":"Nature"},{"issue":"5992","key":"887_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"MC Tsai","year":"2010","unstructured":"Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689\u201393.","journal-title":"Science"},{"issue":"15","key":"887_CR22","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965\u201381.","journal-title":"Cancer Res"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2019.12.028","volume":"503","author":"T Rajagopal","year":"2020","unstructured":"Rajagopal T, Talluri S, Akshaya RL, Dunna NR. HOTAIR LncRNA: a novel oncogenic propellant in human cancer. Clin Chim Acta. 2020;503:1\u201318.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"887_CR24","doi-asserted-by":"publisher","first-page":"10548","DOI":"10.1002\/jcb.28340","volume":"120","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Fan B, Liu F, Song N, Peng Y, Ma W, et al. HOX transcript antisense RNA is elevated in gastric carcinogenesis and regulated by the NF-kappaB pathway. J Cell Biochem. 2019;120(6):10548\u201355.","journal-title":"J Cell Biochem"},{"issue":"41","key":"887_CR25","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1038\/onc.2016.75","volume":"35","author":"AR Ozes","year":"2016","unstructured":"Ozes AR, Miller DF, Ozes ON, Fang F, Liu Y, Matei D, et al. NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016;35(41):5350\u201361.","journal-title":"Oncogene"},{"issue":"1","key":"887_CR26","doi-asserted-by":"publisher","first-page":"15670","DOI":"10.1038\/s41598-018-33722-2","volume":"8","author":"M Obaid","year":"2018","unstructured":"Obaid M, Udden SMN, Deb P, Shihabeddin N, Zaki MH, Mandal SS. LncRNA HOTAIR regulates lipopolysaccharide-induced cytokine expression and inflammatory response in macrophages. Sci Rep. 2018;8(1):15670.","journal-title":"Sci Rep"},{"issue":"2","key":"887_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cells11020187","volume":"11","author":"J Lee","year":"2022","unstructured":"Lee J, Kang H. Role of MicroRNAs and long non-coding RNAs in sarcopenia. Cells. 2022;11(2):187.","journal-title":"Cells"},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1749-6632.2012.06675.x","volume":"1269","author":"H Ueda","year":"2012","unstructured":"Ueda H, Matsunaga H, Halder SK. Prothymosin alpha plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms. Ann N Y Acad Sci. 2012;1269:34\u201343.","journal-title":"Ann N Y Acad Sci"},{"issue":"21","key":"887_CR29","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/S0024-3205(97)00882-5","volume":"61","author":"CL Wu","year":"1997","unstructured":"Wu CL, Shiau AL, Lin CS. Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci. 1997;61(21):2091\u2013101.","journal-title":"Life Sci"},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/ncomms2906","volume":"4","author":"BH Su","year":"2013","unstructured":"Su BH, Tseng YL, Shieh GS, Chen YC, Shiang YC, Wu P, et al. Prothymosin alpha overexpression contributes to the development of pulmonary emphysema. Nat Commun. 2013;4:1906.","journal-title":"Nat Commun"},{"issue":"11","key":"887_CR31","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1210\/jc.2015-2277","volume":"100","author":"YC Su","year":"2015","unstructured":"Su YC, Ou HY, Wu HT, Wu P, Chen YC, Su BH, et al. Prothymosin-alpha overexpression contributes to the development of insulin resistance. J Clin Endocrinol Metab. 2015;100(11):4114\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"887_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.urology.2008.11.060","volume":"74","author":"YC Jou","year":"2009","unstructured":"Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL, et al. Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology. 2009;74(4):951\u20137.","journal-title":"Urology"},{"issue":"17","key":"887_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2174\/0929867324666170518110033","volume":"24","author":"P Samara","year":"2017","unstructured":"Samara P, Karachaliou CE, Ioannou K, Papaioannou NE, Voutsas IF, Zikos C, et al. Prothymosin Alpha: an Alarmin and More. Curr Med Chem. 2017;24(17):1747\u201360.","journal-title":"Curr Med Chem"},{"issue":"28\u201329","key":"887_CR34","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1016\/S0264-410X(01)00130-X","volume":"19","author":"AL Shiau","year":"2001","unstructured":"Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL. Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine. 2001;19(28\u201329):3947\u201356.","journal-title":"Vaccine"},{"issue":"48\u201349","key":"887_CR35","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1016\/j.vaccine.2005.07.004","volume":"23","author":"AL Shiau","year":"2005","unstructured":"Shiau AL, Chen CC, Yo YT, Chu CY, Wang SY, Wu CL. Enhancement of humoral and cellular immune responses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin alpha. Vaccine. 2005;23(48\u201349):5563\u201371.","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"887_CR36","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1517\/14712598.2015.1005597","volume":"15","author":"O Omotuyi","year":"2015","unstructured":"Omotuyi O, Matsunaga H, Ueda H. Evidence for ProTalpha-TLR4\/MD-2 binding: molecular dynamics and gravimetric assay studies. Expert Opin Biol Ther. 2015;15(Suppl 1):S223-229.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"887_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jnc.13356","volume":"135","author":"SK Halder","year":"2015","unstructured":"Halder SK, Matsunaga H, Ishii KJ, Ueda H. Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina. J Neurochem. 2015;135(6):1161\u201377.","journal-title":"J Neurochem"},{"issue":"1","key":"887_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.urology.2008.05.031","volume":"73","author":"YS Tsai","year":"2009","unstructured":"Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT, et al. Aberrant prothymosin-alpha expression in human bladder cancer. Urology. 2009;73(1):188\u201392.","journal-title":"Urology"},{"issue":"2","key":"887_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.urology.2005.08.034","volume":"67","author":"TS Tzai","year":"2006","unstructured":"Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, Tsai HT. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology. 2006;67(2):294\u20139.","journal-title":"Urology"},{"issue":"5","key":"887_CR40","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/j.1523-1755.2005.00268.x","volume":"67","author":"KJ Li","year":"2005","unstructured":"Li KJ, Shiau AL, Chiou YY, Yo YT, Wu CL. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease. Kidney Int. 2005;67(5):1710\u201322.","journal-title":"Kidney Int"},{"key":"887_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101473","volume":"60","author":"FC Kuo","year":"2022","unstructured":"Kuo FC, Huang YC, Yen MR, Lee CH, Hsu KF, Yang HY, et al. Aberrant overexpression of HOTAIR inhibits abdominal adipogenesis through remodelling of genome-wide DNA methylation and transcription. Mol Metab. 2022;60: 101473.","journal-title":"Mol Metab"},{"issue":"1","key":"887_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/ijms22010301","volume":"22","author":"YC Chen","year":"2020","unstructured":"Chen YC, Kuo PY, Chou YC, Chong HE, Hsieh YT, Yang ML, et al. Up-regulated expression of pro-apoptotic long noncoding RNA lincRNA-p21 with enhanced cell apoptosis in lupus nephritis. Int J Mol Sci. 2020;22(1):301.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"887_CR43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/gt.2010.78","volume":"17","author":"CR Wang","year":"2010","unstructured":"Wang CR, Shiau AL, Chen SY, Cheng ZS, Li YT, Lee CH, et al. Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther. 2010;17(10):1225\u201333.","journal-title":"Gene Ther"},{"issue":"1","key":"887_CR44","doi-asserted-by":"publisher","first-page":"C101","DOI":"10.1152\/ajpcell.00344.2015","volume":"311","author":"R Sun","year":"2016","unstructured":"Sun R, Zhang S, Hu W, Lu X, Lou N, Yang Z, et al. Valproic acid attenuates skeletal muscle wasting by inhibiting C\/EBPbeta-regulated atrogin1 expression in cancer cachexia. Am J Physiol Cell Physiol. 2016;311(1):C101-115.","journal-title":"Am J Physiol Cell Physiol"},{"key":"887_CR45","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3389\/fphys.2017.00738","volume":"8","author":"RW Jackman","year":"2017","unstructured":"Jackman RW, Floro J, Yoshimine R, Zitin B, Eiampikul M, El-Jack K, et al. Continuous release of tumor-derived factors improves the modeling of cachexia in muscle cell culture. Front Physiol. 2017;8:738.","journal-title":"Front Physiol"},{"issue":"1","key":"887_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41420-022-00972-z","volume":"8","author":"W Zhang","year":"2022","unstructured":"Zhang W, Sun W, Gu X, Miao C, Feng L, Shen Q, et al. GDF-15 in tumor-derived exosomes promotes muscle atrophy via Bcl-2\/caspase-3 pathway. Cell Death Discov. 2022;8(1):162.","journal-title":"Cell Death Discov"},{"issue":"4","key":"887_CR47","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.20991","volume":"52","author":"CR Wang","year":"2005","unstructured":"Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005;52(4):1319\u201324.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"887_CR48","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"NA Marzouka","year":"2018","unstructured":"Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjodahl G, Hoglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737.","journal-title":"Sci Rep"},{"issue":"21","key":"887_CR49","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"11","key":"887_CR50","doi-asserted-by":"publisher","first-page":"10326","DOI":"10.1074\/jbc.M412643200","volume":"280","author":"SJ Jeong","year":"2005","unstructured":"Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. A novel NF-kappaB pathway involving IKKbeta and p65\/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity. J Biol Chem. 2005;280(11):10326\u201332.","journal-title":"J Biol Chem"},{"issue":"1\u20133","key":"887_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.febslet.2004.06.056","volume":"571","author":"HM Shin","year":"2004","unstructured":"Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004;571(1\u20133):50\u20134.","journal-title":"FEBS Lett"},{"issue":"1","key":"887_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/jpet.104.074484","volume":"312","author":"PL Podolin","year":"2005","unstructured":"Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther. 2005;312(1):373\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"887_CR53","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1172\/JCI115767","volume":"89","author":"G Strassmann","year":"1992","unstructured":"Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89(5):1681\u20134.","journal-title":"J Clin Invest"},{"issue":"4","key":"887_CR54","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI114304","volume":"84","author":"J Satoh","year":"1989","unstructured":"Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest. 1989;84(4):1345\u20138.","journal-title":"J Clin Invest"},{"issue":"20","key":"887_CR55","doi-asserted-by":"publisher","first-page":"15285","DOI":"10.1016\/S0021-9258(18)82467-X","volume":"268","author":"M van Dam","year":"1993","unstructured":"van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, et al. Structure-function analysis of interleukin-6 utilizing human\/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem. 1993;268(20):15285\u201390.","journal-title":"J Biol Chem"},{"issue":"6","key":"887_CR56","doi-asserted-by":"publisher","first-page":"E469","DOI":"10.1152\/ajpendo.00204.2014","volume":"307","author":"SC Bodine","year":"2014","unstructured":"Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx\/atrogin-1. Am J Physiol Endocrinol Metab. 2014;307(6):E469-484.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"887_CR57","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1096\/fj.12-222711","volume":"27","author":"G Zhang","year":"2013","unstructured":"Zhang G, Lin RK, Kwon YT, Li YP. Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2. FASEB J. 2013;27(7):2893\u2013901.","journal-title":"FASEB J"},{"issue":"11","key":"887_CR58","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389\u2013400.","journal-title":"Nat Med"},{"issue":"20","key":"887_CR59","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/MCB.21.20.6913-6926.2001","volume":"21","author":"M Benhar","year":"2001","unstructured":"Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 2001;21(20):6913\u201326.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"887_CR60","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1091\/mbc.12.6.1569","volume":"12","author":"RG Deschesnes","year":"2001","unstructured":"Deschesnes RG, Huot J, Valerie K, Landry J. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol Biol Cell. 2001;12(6):1569\u201382.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"887_CR61","first-page":"321","volume":"16","author":"G Gebauer","year":"2000","unstructured":"Gebauer G, Mirakhur B, Nguyen Q, Shore SK, Simpkins H, Dhanasekaran N. Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008\/C13 cells. Int J Oncol. 2000;16(2):321\u20135.","journal-title":"Int J Oncol"},{"key":"887_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bcp.2016.10.003","volume":"122","author":"YT Lin","year":"2016","unstructured":"Lin YT, Liu YC, Chao CC. Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin. Biochem Pharmacol. 2016;122:80\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"887_CR63","first-page":"227","volume":"1860","author":"C Han","year":"2017","unstructured":"Han C, Shen JK, Hornicek FJ, Kan Q, Duan Z. Regulation of microRNA-1 (miR-1) expression in human cancer. Biochem Biophys Acta. 2017;1860(2):227\u201332.","journal-title":"Biochem Biophys Acta"},{"issue":"5","key":"887_CR64","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/bjc.2011.23","volume":"104","author":"H Yoshino","year":"2011","unstructured":"Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011;104(5):808\u201318.","journal-title":"Br J Cancer"},{"issue":"1","key":"887_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2015.12.013","volume":"410","author":"M Horak","year":"2016","unstructured":"Horak M, Novak J, Bienertova-Vasku J. Muscle-specific microRNAs in skeletal muscle development. Dev Biol. 2016;410(1):1\u201313.","journal-title":"Dev Biol"},{"issue":"15","key":"887_CR66","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-14-3380","volume":"75","author":"YS Chang","year":"2015","unstructured":"Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J, Liu YN. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 2015;75(15):3077\u201386.","journal-title":"Cancer Res"},{"key":"887_CR67","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1423-0127-18-80","volume":"18","author":"CD Wu","year":"2011","unstructured":"Wu CD, Kuo YS, Wu HC, Lin CT. MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci. 2011;18:80.","journal-title":"J Biomed Sci"},{"issue":"7","key":"887_CR68","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117\u201334.","journal-title":"Cell"},{"issue":"3","key":"887_CR69","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/JTO.0b013e31827ed0ff","volume":"8","author":"FR Hirsch","year":"2013","unstructured":"Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013;8(3):373\u201384.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"887_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1464-410X.2009.09101.x","volume":"106","author":"RS Pruthi","year":"2010","unstructured":"Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106(3):349\u201354.","journal-title":"BJU Int"},{"issue":"1","key":"887_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.juro.2014.07.121","volume":"193","author":"BA Mooso","year":"2015","unstructured":"Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere WRW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015;193(1):19\u201329.","journal-title":"J Urol"},{"key":"887_CR72","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/jcsm.12985","volume":"13","author":"BZC Weber","year":"2022","unstructured":"Weber BZC, Agca S, Domaniku A, Bilgic SN, Arabaci DH, Kir S. Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia. J Cachexia Sarcopenia Muscle. 2022;13:1582.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"887_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/1759-7714.12545","volume":"9","author":"K Kakinuma","year":"2018","unstructured":"Kakinuma K, Tsuruoka H, Morikawa K, Furuya N, Inoue T, Miyazawa T, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer. Thorac Cancer. 2018;9(1):99\u2013104.","journal-title":"Thorac Cancer"},{"issue":"11","key":"887_CR74","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ncb1101-1014","volume":"3","author":"SC Bodine","year":"2001","unstructured":"Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt\/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3(11):1014\u20139.","journal-title":"Nat Cell Biol"},{"issue":"10","key":"887_CR75","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3390\/nu12103101","volume":"12","author":"E Rinninella","year":"2020","unstructured":"Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Ponziani FR, et al. Skeletal muscle loss during multikinase inhibitors therapy: molecular pathways, clinical implications, and nutritional challenges. Nutrients. 2020;12(10):3101.","journal-title":"Nutrients"},{"issue":"10","key":"887_CR76","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2217\/fon-2017-0499","volume":"14","author":"S Rossi","year":"2018","unstructured":"Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, et al. Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations? Future Oncol. 2018;14(10):919\u201326.","journal-title":"Future Oncol"},{"issue":"3","key":"887_CR77","first-page":"853","volume":"26","author":"A Kucukarda","year":"2021","unstructured":"Kucukarda A, Gokyer A, Gokmen I, Bekir HM, Kostek O, Kurt N, et al. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival. J BUON. 2021;26(3):853\u201360.","journal-title":"J BUON"},{"issue":"11","key":"887_CR78","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s12094-019-02079-x","volume":"21","author":"O Kostek","year":"2019","unstructured":"Kostek O, Demircan NC, Gokyer A, Kucukarda A, Sunal BS, Hacioglu MB, et al. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. Clin Transl Oncol. 2019;21(11):1510\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"887_CR79","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","volume":"61","author":"O Tetsu","year":"2016","unstructured":"Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug resistance to EGFR inhibitors in lung cancer. Chemotherapy. 2016;61(5):223\u201335.","journal-title":"Chemotherapy"},{"issue":"1","key":"887_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/jcsm.12035","volume":"7","author":"M Toledo","year":"2016","unstructured":"Toledo M, Penna F, Oliva F, Luque M, Betancourt A, Marmonti E, et al. A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. J Cachexia Sarcopenia Muscle. 2016;7(1):48\u201359.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"13","key":"887_CR81","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/onc.2012.193","volume":"32","author":"K Kim","year":"2013","unstructured":"Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616\u201325.","journal-title":"Oncogene"},{"issue":"4","key":"887_CR82","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ijc.20270","volume":"111","author":"MH Zaki","year":"2004","unstructured":"Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer. 2004;111(4):592\u20135.","journal-title":"Int J Cancer"},{"issue":"7","key":"887_CR83","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11605-008-0505-z","volume":"12","author":"J Bachmann","year":"2008","unstructured":"Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12(7):1193\u2013201.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"887_CR84","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41420-022-01174-3","volume":"8","author":"C Zhu","year":"2022","unstructured":"Zhu C, Wang X, Wang Y, Wang K. Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance. Cell Death Discov. 2022;8(1):383.","journal-title":"Cell Death Discov"},{"issue":"1","key":"887_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/labinvest.2015.123","volume":"96","author":"S Fang","year":"2016","unstructured":"Fang S, Gao H, Tong Y, Yang J, Tang R, Niu Y, et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab Invest. 2016;96(1):60\u20138.","journal-title":"Lab Invest"},{"issue":"8","key":"887_CR86","first-page":"2997","volume":"12","author":"R Chen","year":"2019","unstructured":"Chen R, Chen B, Li D, Wang Q, Zhu Y, Li M, et al. HOTAIR contributes to chemoresistance by activating NF-kappaB signaling in small-cell lung cancer. Int J Clin Exp Pathol. 2019;12(8):2997\u20133004.","journal-title":"Int J Clin Exp Pathol"},{"issue":"Pt B","key":"887_CR87","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ijbiomac.2017.10.154","volume":"107","author":"C Cheng","year":"2018","unstructured":"Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K\/Akt and Wnt\/beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620\u20139.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"887_CR88","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-016-2964-3","volume":"77","author":"C Shang","year":"2016","unstructured":"Shang C, Guo Y, Zhang H, Xue YX. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol. 2016;77(3):507\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"887_CR89","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597\u2013605.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"887_CR90","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531\u201343.","journal-title":"Cell"},{"issue":"12","key":"887_CR91","doi-asserted-by":"publisher","first-page":"djv274","DOI":"10.1093\/jnci\/djv274","volume":"107","author":"YC Tseng","year":"2015","unstructured":"Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, et al. Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia. J Natl Cancer Inst. 2015;107(12):djv274.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"887_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.cell.2011.11.055","volume":"147","author":"I Ulitsky","year":"2011","unstructured":"Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell. 2011;147(7):1537\u201350.","journal-title":"Cell"},{"key":"887_CR93","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2148-11-102","volume":"11","author":"S He","year":"2011","unstructured":"He S, Liu S, Zhu H. The sequence, structure and evolutionary features of HOTAIR in mammals. BMC Evol Biol. 2011;11:102.","journal-title":"BMC Evol Biol"},{"issue":"5","key":"887_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002071","volume":"7","author":"P Schorderet","year":"2011","unstructured":"Schorderet P, Duboule D. Structural and functional differences in the long non-coding RNA hotair in mouse and human. PLoS Genet. 2011;7(5): e1002071.","journal-title":"PLoS Genet"},{"issue":"1","key":"887_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.celrep.2013.09.003","volume":"5","author":"L Li","year":"2013","unstructured":"Li L, Liu B, Wapinski OL, Tsai MC, Qu K, Zhang J, et al. Targeted disruption of Hotair leads to homeotic transformation and gene derepression. Cell Rep. 2013;5(1):3\u201312.","journal-title":"Cell Rep"},{"issue":"3","key":"887_CR96","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.mco.0000165003.16578.2d","volume":"8","author":"RA Frost","year":"2005","unstructured":"Frost RA, Lang CH. Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care. 2005;8(3):255\u201363.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"9","key":"887_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183662","volume":"12","author":"DW Edwardson","year":"2017","unstructured":"Edwardson DW, Boudreau J, Mapletoft J, Lanner C, Kovala AT, Parissenti AM. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS ONE. 2017;12(9): e0183662.","journal-title":"PLoS ONE"},{"issue":"2","key":"887_CR98","first-page":"231","volume":"110","author":"HW Pogrebniak","year":"1991","unstructured":"Pogrebniak HW, Matthews W, Pass HI. Chemotherapy amplifies production of tumor necrosis factor. Surgery. 1991;110(2):231\u20137.","journal-title":"Surgery"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-022-00887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-022-00887-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-022-00887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:34:13Z","timestamp":1670614453000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-022-00887-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1186\/s12929-022-00887-y","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of clinical bladder tumor samples in the present study was approved by the Institutional Review Board (IRB) of NCKU Hospital, and informed consent was obtained from each patient (IRB number: A-ER-106-451). The NCKUH IRB is organized and operated according to the laws and regulations of ICH-GCP and Central Competent Authorities. The conduct of the study adhered to the tenets of the Declaration of Helsinki. Regarding animal experiments, the experimental protocols adhered to the rules of the Animal Protection Act of Taiwan and were approved by the Institutional Animal Care and Use Committee (IACUC) of NCKU (IACUC approval number: 106170 and 107231).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}